Other new agents for Hodgkin lymphoma Journal Article


Authors: Moskowitz, A. J.; Younes, A.
Article Title: Other new agents for Hodgkin lymphoma
Abstract: Brentuximab vedotin (BV) and the PD-1 inhibitors have dramatically expanded options and improved outcomes for patients with relapsed or refractory Hodgkin lymphoma (HL). For patients with disease progression following BV, PD-1 inhibitors, and autologous stem cell transplant (ASCT), treatment options are limited. Additional classes of drugs have been found to be effective for HL, including drugs that target the PI3-kinase (PI3K) pathway, histone deacetylase (HDAC) inhibitors, as well as immune modulatory agents. These agents target both the Hodgkin Reed-Sternberg cells as well as the tumor microenvironment. While these targeted drugs are options for patients who have progressed after BV or PD-1 inhibitors, there is good rationale for combining some of these agents with either BV or PD-1 inhibitors to improve response rates or durability. Such combinations are under investigation in clinical trials. Emerging therapies for HL include the anti-CD25 antibody drug conjugate, camidanlumab, as well as other therapies that target CD30 such as anti-CD30 chimeric antigen receptor (CAR)-T cells and the bispecific antibody, AFM-13. Newer targeted agents, emerging therapies, as well as studies evaluating novel combinations will be reviewed. © Springer Nature Switzerland AG 2020.
Keywords: lenalidomide; hodgkin lymphoma; cd25; hdac inhibitor; car-t; pi3-kinase inhibitors
Journal Title: Hematologic Malignancies
ISSN: 2197-9766
Publisher: Springer  
Date Published: 2020-01-01
Start Page: 411
End Page: 416
Language: English
DOI: 10.1007/978-3-030-32482-7_24
PROVIDER: scopus
DOI/URL:
Notes: Chapter 24 in "Hodgkin Lymphoma - A Comprehensive Review. 3rd ed" (ISBN: 978-3-030-32481-0) -- Export Date: 1 June 2020 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Alison Moskowitz
    179 Moskowitz
  2. Anas Younes
    248 Younes